5/15/2012
Intezyne Adds Chief Business Officer Daniel Devers to Management Team
1/25/2012
Intezyne Scientists Gain Cover Art for the Journal of Polymer Chemistry
6/14/2011
Intezyne Featured in 83 Degrees
1/25/2011
Intezyne Named Company 'On The Rise' by Drug Development & Delivery Magazine
7/19/2010
Intezyne CEO Featured in Drug Delivery Technology
Intezyne offers a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT™ Method to limit chemotherapeutics’ anti-tumor activity to within the tumor itself, thereby sparing healthy tissues. To date, the IVECT Method has shown positive preclinical efficacy and safety profiles in multiple cancer models versus best-in-class chemotherapeutic agents. Ultimately, the IVECT Method has demonstrated preclinical proof-of-concept in a number of therapeutic and diagnostic categories, giving the Company the opportunity to monetize this asset through licensing agreements outside of Intezyne’s primary oncology focus.
COMPANY PROFILE | OUR TECHNOLOGY | NEWS | INVESTORS | CONTACT US | INTEZYNE HOME
Intezyne © 2013